Programs – Publication Format

Recent Developments in Medical Affairs Reputation and Hemophilia A Management in the US (2025)

2 days ago talkbio0Tagged Acquired (qualifier value), Centers for Disease Control and Prevention (U.S.), federal funding, gene therapy, Health Policy, Hemophilia A, Hemophilia A Pipeline, Hemophilia Treatment Centers, HRSA, Medical Affairs, Programs - Publication Format, public health policy, reputation, U.S.

Medical Affairs; Reputation; Hemophilia A; US; 2025; Gene Therapy; Public Health Policies; Hemophilia Treatment Centers; 340B Program; Federal Funding; Acquired Hemophilia A Pipeline; Healthcare Policy; CDC; HRSA

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

1 month ago talkbio0Tagged AFFIRM-1 phase 3 trial, BNC210, Clinical trial failure, Discontinuation (procedure), Merck, Neuphoria, Neuroscience discipline, Partnership, Phobia, Social, Post-Traumatic Stress Disorder, Programs - Publication Format, Schizophrenia

Neuphoria Therapeutics; BNC210; social anxiety disorder; AFFIRM-1 phase 3 trial; clinical trial failure; program discontinuation; PTSD; Merck partnership; Minerva Neurosciences; schizophrenia therapy

EMD Serono Joins TrumpRx in Affordability Push; Roche Launches DTC Program

2 months ago talkbio0Tagged Affordability, CNPV, direct-to-consumer sales, Ditiocarb, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Pergoveris, Programs - Publication Format, Roche (company), serono, tariffs, TrumpRx, White House Executive Order

EMD Serono; TrumpRx; IVF therapies; affordability; fertility drugs; Direct-to-Consumer sales; Roche; DTC program; White House Executive Order; Section 232 tariffs; CNPV program; Pergoveris

Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide

2 months ago talkbio0Tagged Affordability, Diabetes, Insulin, Insurance, Medicare, monthly, Programs - Publication Format, sanofi, United States

Sanofi; Insulin; $35 monthly program; Insulins Valyou Savings Program; diabetes; insurance coverage; Medicare; affordability; United States

Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Drug Rocatinlimab

3 months ago talkbio0Tagged amgen, ASCEND trial, Dermatitis, Atopic, Eczema, Kyowa Kirin, Long-term, OX40 receptor, Programs - Publication Format, Rocatinlimab, Rocket, Safety

Amgen; Kyowa Kirin; rocatinlimab; atopic dermatitis; OX40 receptor; ASCEND trial; ROCKET program; long-term safety; eczema

Recent Developments in Building Measurable Patient Support Programs (2025)

5 months ago talkbio0Tagged 2025, care activity, collaborative healthcare, Efficiency, Financial cost, measurable outcomes, Medicare reforms, Programs - Publication Format, trends qualifier

patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care

iTeos to Shut Down Operations After TIGIT Therapy Setback

6 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

Cigna’s Evernorth unveils 2 new programs aimed at GLP-1s

7 months ago talkbio0Tagged Cigna 's, Enhance (action), GLP-1s, Glucagon-Like Peptide 1, Pharmaceutical Services, Pharmacy facility, Programs - Publication Format

Programs – Publication Format, Glucagon-Like Peptide 1, Cigna ‘s, GLP-1s, Pharmacy facility, Enhance (action), Pharmaceutical Services

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

7 months ago talkbio0Tagged Autoimmune Diseases, B cell immunomodulator program, biology (field), Flatulence, Nordisk alliance, OCT50, Programs - Publication Format

Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges

CMS would absorb 340B drug discount program under leaked HHS reorganization proposal

7 months ago talkbio0Tagged 340B, Centers for Medicare and Medicaid Services, Changing, CMS, drug discount program, HHS, Leaked, Policy, Programs - Publication Format, proposal - intent, reorganization, United States Health Resources and Services Administration

340B, Centers for Medicare and Medicaid Services, HHS, reorganization, Programs – Publication Format, proposal – intent, drug discount program, United States Health Resources and Services Administration, CMS, Policy, Leaked, Changing